All In Biotech

Investigational drug · Phase 2

single CNCT19

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

11

Any phase or sponsor naming "single CNCT19"

First trial start

2020

Oct 26, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "single CNCT19", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed or Refractory Acute Lymphoblastic Leukemia
  • B-cell Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma

Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lymphoma (non-Hodgkin) · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "single CNCT19" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.